Twist Bioscience to Present at SynBioBeta London 2017

SAN FRANCISCO, April 4, 2017 /PRNewswire/ -- Twist Bioscience, a company accelerating science and innovation through rapid, high-quality DNA synthesis, today announced that Emily Leproust, Ph.D., CEO of Twist Bioscience will present a corporate update at SynBioBeta London 2017 today at 3:35pm local time.

"As the company reaches operational maturity, consistently delivering over 10,000 genes to customers every month, we are expanding our product mix, offering genes up to 3.2kB, oligo pools and highest quality DNA variant libraries," commented Emily M. Leproust, Ph.D., CEO of Twist Bioscience. "Since we entered our commercialization phase in March of 2016, we have achieved significant momentum serving the high-volume customer segment of the DNA synthesis market, where a small number of companies represent a meaningful portion of the demand for synthetic DNA. Moving forward, in addition to continuing to providing superior service for these customers, we are focused on implementing solutions that will allow us to effectively serve a larger number of customers with lower volume synthetic DNA needs."

Dr. Leproust continued, "This summer, we intend to introduce our innovative eCommerce platform to provide a seamless end-to-end solution for this much larger customer base. In addition, we will continue to forward-integrate into the drug discovery and DNA data storage arenas where our proprietary synthesis technologies are a natural platform for separate vertical businesses."

About Twist Bioscience

At Twist Bioscience, our expertise is accelerating science and innovation by leveraging the power of scale. We have developed a proprietary semiconductor-based synthetic DNA manufacturing process featuring a high throughput silicon platform capable of producing synthetic biology tools, including genes, oligonucleotide pools and variant libraries. By synthesizing DNA on silicon instead of on traditional 96-well plastic plates, our platform overcomes the current inefficiencies of synthetic DNA production, and enables cost-effective, rapid, high-quality and high throughput synthetic gene production, which in turn, expedites the design, build and test cycle to enable personalized medicines, pharmaceuticals, sustainable chemical production, improved agriculture production, diagnostics and biodetection. We are also developing new technologies to address large scale data storage. For more information, please visit www.twistbioscience.com. Twist Bioscience is on Twitter. Sign up to follow our Twitter feed @TwistBioscience at https://twitter.com/TwistBioscience.

SOURCE Twist Bioscience

Related Links

http://www.twistbioscience.com